Andrea Tremaine
Family Medicine · Tigard, ORNPI 1952735086
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 183 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 14.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $907 and has fallen 66.6% since, to $303 in 2025. Among family medicine clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 183 payments — averaging $19.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$489
- AbbVie$376
- Pfizer$248
- Merck$224
- Novo Nordisk$203
- AstraZeneca$198
- plus $2K from 33 others
Across 1 payment — averaging $500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Lucid Diagnostics Inc.$500
What the payments were for
- Food & beverage$3,475100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 24 | $489 |
| AbbVie(2 entities) | 22 | $376 |
| Pfizer | 14 | $248 |
| Merck | 17 | $224 |
| Novo Nordisk | 10 | $203 |
| AstraZeneca | 12 | $198 |
| GSK | 8 | $145 |
| Boehringer Ingelheim | 5 | $128 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $122 |
| Amgen(2 entities) | 7 | $116 |
| Exact Sciences | 4 | $105 |
| Eisai Inc. | 5 | $93 |
| Lilly USA, LLC | 4 | $75 |
| Inspire Medical Systems, Inc. | 2 | $75 |
| Daiichi Sankyo Inc. | 3 | $68 |
| Gilead | 3 | $66 |
| Sanofi Pasteur Inc. | 3 | $64 |
| Shire North American Group Inc | 3 | $57 |
| Hologic Sales And Service, LLC | 2 | $51 |
| Biohaven Pharmaceuticals, Inc. | 2 | $47 |
| Abbott | 2 | $46 |
| Boston Scientific | 1 | $43 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $41 |
| Teva Pharmaceuticals USA, Inc. | 3 | $40 |
| Amarin Pharma, Inc. | 2 | $35 |
| Medtronic(2 entities) | 2 | $35 |
| Phathom Pharmaceuticals, Inc. | 1 | $32 |
| Lundbeck LLC | 1 | $31 |
| Sanofi-aventis U.S. LLC | 1 | $28 |
| Baxter Healthcare | 1 | $28 |
| Kaleo, Inc. | 1 | $28 |
| Vertex | 1 | $26 |
| Lucid Diagnostics Inc. | 2 | $24 |
| Novartis | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Ironshore Pharmaceuticals Inc. | 1 | $16 |
| Exeltis, USA Inc. | 1 | $15 |
| Si-bone, Inc. | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
How this compares
$3,481 in reported general payments places this provider in the 95th percentile of 1,221 family medicine providers in Oregon.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 13 | $15,339 |
| Xigduo XrDapaglifloz Propaned/Metformin | 11 | $9,475 |
| EliquisApixaban | 14 | $9,255 |
| Estradiol | 17 | $2,065 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 22 | $1,214 |
| Atorvastatin Calcium | 59 | $725 |
| Losartan Potassium | 46 | $691 |
| Levothyroxine Sodium | 68 | $664 |
| Omeprazole | 33 | $579 |
| Gabapentin | 12 | $498 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 31 | $471 |
| Pravastatin Sodium | 22 | $363 |
| Bupropion XlBupropion Hcl | 11 | $299 |
| Rosuvastatin Calcium | 15 | $273 |
| Amlodipine Besylate | 43 | $268 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia | $224 | $15,33913 claims |
| PfizerEliquis | $248 | $9,25514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,221 family medicine providers in Oregon.
Other family medicine in Tigard
- Standley AdamekTigard$4K
- Michael PhelpsTigard$3K
- Eden MillerBend$1.7M
- Anil RajaniHood River$325K
- Stephen NelsonMedford$101K
- Karen KahnAshland$86K
- Robert GobboPortland$53K
- Kevin MillerSisters$39K
- Morris MaizelsCentral Point$25K
- Maureen MaysPortland$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.